Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 10/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 8/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.51 |
| ▸ | PIM1 | P11309 | 7/20 | 0.51 |
| ▸ | GSK3B | P49841 | 7/20 | 0.51 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 6/20 | 0.35 |
| ▸ | JAK1 | P23458 | 6/20 | 0.35 |
| ▸ | TYK2 | P29597 | 6/20 | 0.35 |
| ▸ | JAK3 | P52333 | 6/20 | 0.35 |
| ▸ | IL17A | Q16552 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL456367 | 0.91 | PIK3CD (0.50) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL2215185 | 0.90 | PIK3CD (0.48) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL461505 | 0.89 | PIK3CD (0.65) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL459146 | 0.89 | PIK3CD (0.51) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL456830 | 0.85 | PIK3CD (0.51) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL2212860 | 0.82 | PIK3CD (0.53) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL2212188 | 0.81 | PIK3CD (0.46) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL457078 | 0.81 | PIK3CD (0.45) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL2214906 | 0.80 | PIK3CD (0.65) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 | |
| SCHEMBL2215238 | 0.80 | PIK3CD (0.43) | PIK3CDPIK3CBPIK3CGPIK3CAPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | claimed |
| EP-2300437-B1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | claimed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | claimed |
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| EP-2300437-B1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | disclosed |
| EP-2613781-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| WO-2009147188-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | PIK3CA, PIK3CD, PI4KA | PIK3CD 2/4885PIK3CB 6/4885PIK3CG 15/4885 |
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | PIK3CD 2938/4885PIK3CB 1706/4885PIK3CG 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.